Etanercept in patients with moderate to severe plaque psoriasis: a retrospective case cohort analysis

被引：0

作者：

Perera, G. ^{[1
]}

Fonia, A. ^{[1
]}

Smith, C. ^{[1
]}

Barker, J. N. W. N. ^{[1
]}

机构：

[1] St Johns Inst Dermatol, London, England

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2009年 / 161卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：26 / 27

页数：2

共 50 条

[21] Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
Gottlieb, A. B.
Leonardi, C.
Kerdel, F.
Mehlis, S.
Olds, M.
Williams, D. A.
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (03) : 652 - 660
[22] Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis
Hutmacher, Matthew M.
Nestorov, Ivan
Ludden, Tom
Zitnik, Ralph
Banfield, Christopher
JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (02): : 238 - 248
[23] Etanercept improves symptoms of depression in patients with moderate to severe psoriasis
Krishnan, R
Lalla, D
Woolley, M
Zitnik, R
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P184 - P184
[24] COST PER RESPONDER OF USTEKINUMAB VERSUS ETANERCEPT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS FROM THE ACCEPT TRIAL
Feldman, S. R.
Augustin, M.
Martin, S.
Szapary, P.
Schenkel, B.
VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
[25] Patients with moderate to severe plaque psoriasis show improvement in patient satisfaction with etanercept therapy: a 12-week interim analysis
de Rie, M. A.
Griffiths, C. E. M.
Desris, T. A.
Robertson, D.
Freundlich, B.
Chang, D. J.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 : 57 - 57
[26] Etanercept in combination with narrowband ultraviolet light B for the treatment of moderate to severe plaque psoriasis
Moore, Angela Yen
Richardson, Blakely S.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB136 - AB136
[27] Experience of pain in patients with moderate to severe plaque psoriasis
Revicki, Dennis
Wilson, Hilary D.
Pinto, Lionel A.
Viswanathan, Hema
QUALITY OF LIFE RESEARCH, 2014, 23 : 102 - 102
[28] Efficacy and safety results of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
Menter, A.
Gottlieb, A.
Leonardi, C.
Kerdel, F.
Gu, Y.
Valdes, J.
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 : 38 - 39
[29] Cost per responder of apremilast and etanercept in patients with moderate to severe plaque psoriasis using results from LIBERATE
Tencer, Tom
Clancy, Zoe
Zhang, Frank
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB242 - AB242
[30] Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice
Vender, Ron
Lynde, Charles
Gilbert, Martin
Ho, Vincent
Sapra, Sheetal
Poulin-Costello, Melanie
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2012, 16 (06) : 407 - 416

← 1 2 3 4 5 →